Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube

Gynecologic Oncology

Volumn 64, Issue 1, 1997, Pages 38-48

  Zheng, Wenxin ^a   Sung, C James ^b   Cao, Peiqin ^c   Zhang, Zuo Feng ^c   Cai, Ruya ^b   Godwin, Thomas A ^d   Kramer, Elmer E ^e   Lauchlan, Stuart C ^b,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA;

EID: 0031031504     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4519     Document Type: Article

References (52)

1. 1. Cordon-Cardo, C. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia, Am. J. Pathol. 147, 545-560 (1995).
2. 2. Umesh, M., Wolf, D., and Frossard, P. M. BanII and ScaI RFLPs at the human p53 gene locus, Nucleic Acids Res. 16, 7757-7762 (1988).
3. 3. Zheng, W., Cao, P., Zheng, M., Kramer, E. E., and Godwin, T. A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes, Gynecol. Oncol. 61, 165-172 (1996).
4. 4. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers, Am. J. Obstet. Gynecol. 170, 246-252 (1994).
5. 5. Lacy, M. Q., Hartman, L. C., Keeney, G. L., Cha, S. C., Wieand, H. S., Podratzkc, K. C., and Roche, P. C. c-erbB-2 and p53 expression in fallopian tube carcinoma, Cancer 75, 2891-2896 (1995).
6. 6. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers, Science 253, 49-53 (1991).
7. 7. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction, Cell 709, 523-526 (1992).
8. 8. Montenarh, M. Functional implications of the growth-suppressor/oncoprotein p53, Int. J. Oncol. 1, 37-45 (1992).
9. 9. Harris, C. C. The p53 tumor supressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment, Science 262, 1980-1981 (1991).
10. 10. Dodson, M. G., Ford, J. H., and Averette, H. E. Clinical aspects of fallopian tube carcinoma, Obstet. Gynecol. 36, 935-939 (1970).
11. 11. Czernobilsky, B., and Lifschitz-Mercer, B. The ovary and fallopian tube, in Principles and practice of surgical pathology (S. G. Silverberg, Ed.), Churchill Livingstone, New York, 2nd ed., pp. 1817-1818 (1990).
12. 12. Bardi, G., Sukhikh, T., Pandis, N., Holund, B., and Heim, S. Complex karyotypic abnormalities in a primary carcinoma of the fallopian tube, Genes Chromosom. Cancer 10, 207-209 (1994).
13. 13. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res. 54, 4855-4878 (1994).
14. 14. Runebaum, I. B., Tong, X. W., Mobus, V. J., Kieback, D. G., Rosenthal, H. E., and Kreienberg, R. p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6, FEBS Lett. 353, 29-32 (1994).
15. 15. Cancer Committee of the International Federation of Gynecology and Obstetrics. Staging announcement: FIGO Cancer Committee, Gynecol. Oncol. 25, 383-385 (1986).
16. 16. Hu, C. Y., Taymor, M. L., and Hertig, A. T. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 59, 58-67 (1950).
17. 17. Zheng, W., Wolf, S., Kramer, E. E., and Hoda, S. Borderline serous tumor of the fallopian tube. Am. J. Surg. Pathol. 20, 30-35 (1996).
18. 18. Wheeler, J. E. Diseases of the fallopian tube, in Blaustein's Pathology of the female genital tract, (R. J. Kurman, Ed.), Springer-Verlag, New York, 4th ed., pp. 547-548 (1994).
19. 19. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression, Eur. J. Biochem. 159, 529-534 (1986).
20. 20. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular cloning: A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 2nd ed., Vol. 13, pp. 45-57 (1989).
21. 21. Spinardi, L., Mazars, R., and Theillet, C. Products for an improved detection of mutations by SSCP, Nucleic Acids Res. 19, 4009-4013 (1991).
22. 22. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction, Genomics 5, 874-879 (1989).
23. 23. Mehta, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in r × c contingency tables, J. Am. Stat. Assoc. 78, 427-434 (1983).
24. 24. Kaplan, E. L., and Meier, P. Non-parametric estimation from incomplete observations, Am. Stat. Assoc. J. 53, 457-481 (1958).
25. 25. Peto, R., Pike, M. C., and Armitage, P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, Br. J. Cancer 35, 1-39 (1977).
26. 26. SAS Institute Inc. SAS/STAT User Guide. Version 6. SAS Institute Inc. Cary, NC (1990).
27. 27. Chang, F., Syrjanen, S., and Syrjanen, K. Implications of the p53 tumor-suppressor gene in clinical oncology, J. Clin. Oncol. 13, 1009-1022 (1995).
28. 28. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Vandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer, Proc. Natl. Acad. Sci. USA 90, 4961-4965 (1993).
29. 29. Finlay, C. A., Hinds, P. W., Tan, T. W., Eliyahu, D., Oren, E. M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half life, Mol. Cell. Biol. 8, 531-539 (1988).
30. 30. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., and Burchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res. 51, 2979-2984 (1991).
31. 31. Inoue, M., Fujita, M., Enomoto, T., Morimato, H., Monden, T., Shimano, T., and Tanizawa, O. Immunohistochemical analysis of p53 in gynecologic tumors, Am. J. Clin. Pathol. 102, 665-670 (1994).
32. 32. Sasano, H., Comerford, J., Wilkinson, D. S., Schwartz, A., and Garrett, C. T. Serous papillary adenonocarcinoma of the endometrium: Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry, Cancer 65, 1545-1551 (1990).
33. 33. Kaston, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51, 6304-6311 (1991).
34. 34. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage, Proc. Natl. Acad. Sci. USA 90, 3988-3992 (1992).
35. 35. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis, Cancer Res. 50, 7717-7722 (1990).
36. 36. Wang, L. D., Hong, J. Y., Qiu, S. L., Gao, H., and Yang, C. S. Accumulation of p53 protein in human esophageal precancerous lesions: A possible early biomarker for carcinogenesis, Cancer Res. 53, 1783-1787 (1993).
37. 37. Shiao, Y. H., Rugge, M., Correa, P., Lehmann, H. P., and Scheer, W. D. p53 alteration in gastric precancerous lesions, Am. J. Pathol. 144, 511-517 (1994).
38. 38. Kaklamanis, L., Gatter, K. C., Mortensen, N., Baigrie, R. T., Heryet, A., Lane, D. P., and Harris, A. L. p53 expression in colorectal adenomas, Am. J. Pathol. 142, 87-93 (1993).
39. 39. Nuorva, K., Soini, Y., Kamel, D., Autio-Harmanien, H., Risteli, L., Risteli, J., and Paeakkeo, P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas, Am. J. Pathol. 142, 725-732 (1993).
40. 40. Dolcetti, R., Doglioni, C., Maestro, R., Gasparotto, D., Barzan, L., Pastone, A., and Romnelli, M. p53 overexpression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications, Int. J. Cancer 52, 178-182 (1992).
41. 41. Shin, D. M., Kim, K., Ro, J. Y., Hittelman, J., Roth, J. A., Hong, W. K., and Hittelman, W. N. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis, Cancer Res. 54, 321-326 (1994).
42. 42. Isacson, C., Levine, R., Tashiro, K., Cho, R., and Hedrick, L. p53 gene mutations are common in uterine serous carcinomas and may occur as an early event in their pathogenesis, Mod. Pathol. 9, 91A (1996).
43. 43. Bourhis, J., Bosq, J., Wilson, G. D., Bressae, B., Talbot, M., Leridant, A. M., Dendale, R., Janin, N., and Armend, J. P. Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer, Int. J. Cancer 57, 458-462 (1994).
44. 44. Casson, A. G., Manolopoulos, B., Troster, M., Kerkvillet, N., Omallery, F., Inculet, R., Finley, R., and Roth, J. A. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer, Am. J. Surg. 167, 52-57 (1994).
45. 45. Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., and Silvestre, F. p53 expression and prognosis in gastric carcinoma, Int. J. Cancer 50, 859-862 (1992).
46. 46. Remvikos, Y., Tominaga, O., Hammel, P., Hamelin, R., Trouvat, V., and Thomas, G. Increased p53 protein content of colorectal tumors correlates with poor survival, Br. J. Cancer 66, 758-764 (1992).
47. 47. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer, J. Natl. Cancer Inst. 85, 2018-2023 (1993).
48. 48. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression, J. Natl. Cancer Inst. 85, 53-59 (1993).
49. 49. Visakorpi, T., Kallioniemi, O. P., Keikkinen, A., Hyytinen, E., Koivisto, P., and Pulmberg, C. Small subgroup of aggressive, highly proliferative protatic carcinomas defined by p53 accumulation, J. Natl. Cancer Inst. 84, 883-887 (1992).
50. 50. Drobnjak, M., Latres, E., Pollack, D., Karpeh, M., Dudas, M., Woodruff, J. M., Brennan, M. F., and Cordon-Cardo, C. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki67 in adult soft-tissue sarcomas, J. Natl. Cancer Inst. 86, 549-554 (1994).
51. 51. Thor, A. D., Moore, D. H. II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., and Chen, L. C. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers, J. Natl. Cancer Inst. 84, 845-855 (1992).
52. 52. Bosari, S., Viale, G., Radaelli, T., Bosari, P., Bonoldi, E., and Coggi, G. p53 accumulation in ovarian carcinomas and its prognostic implications, Hum. Pathol. 24, 1175-1179 (1993).